Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Total Non-Current Liabilities (2016 - 2025)

Ani Pharmaceuticals' Total Non-Current Liabilities history spans 14 years, with the latest figure at $887.5 million for Q4 2025.

  • For Q4 2025, Total Non-Current Liabilities rose 4.49% year-over-year to $887.5 million; the TTM value through Dec 2025 reached $887.5 million, up 4.49%, while the annual FY2025 figure was $887.5 million, 4.49% up from the prior year.
  • Total Non-Current Liabilities for Q4 2025 was $887.5 million at Ani Pharmaceuticals, roughly flat from $891.1 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $891.1 million in Q3 2025 and bottomed at $251.8 million in Q1 2021.
  • The 5-year median for Total Non-Current Liabilities is $420.1 million (2023), against an average of $505.3 million.
  • The largest annual shift saw Total Non-Current Liabilities dropped 5.87% in 2021 before it surged 101.59% in 2025.
  • A 5-year view of Total Non-Current Liabilities shows it stood at $381.9 million in 2021, then increased by 1.21% to $386.5 million in 2022, then increased by 12.58% to $435.1 million in 2023, then surged by 95.21% to $849.4 million in 2024, then grew by 4.49% to $887.5 million in 2025.
  • Per Business Quant, the three most recent readings for ANIP's Total Non-Current Liabilities are $887.5 million (Q4 2025), $891.1 million (Q3 2025), and $863.3 million (Q2 2025).